- Home
- TYRA vs CHCT Comparison
TYRA vs CHCT Comparison
Compare TYRA & CHCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TYRA
- CHCT
- Stock Information
- Founded
- TYRA 2018
- CHCT 2014
- Country
- TYRA United States
- CHCT United States
- Employees
- TYRA N/A
- CHCT N/A
- Industry
- TYRA Biotechnology: Pharmaceutical Preparations
- CHCT Real Estate Investment Trusts
- Sector
- TYRA Health Care
- CHCT Real Estate
- Exchange
- TYRA Nasdaq
- CHCT Nasdaq
- Market Cap
- TYRA 580.2M
- CHCT 491.1M
- IPO Year
- TYRA 2021
- CHCT 2015
- Fundamental
- Price
- TYRA $10.37
- CHCT $15.34
- Analyst Decision
- TYRA Strong Buy
- CHCT Buy
- Analyst Count
- TYRA 7
- CHCT 4
- Target Price
- TYRA $30.86
- CHCT $21.00
- AVG Volume (30 Days)
- TYRA 231.1K
- CHCT 267.2K
- Earning Date
- TYRA 08-11-2025
- CHCT 07-29-2025
- Dividend Yield
- TYRA N/A
- CHCT 12.32%
- EPS Growth
- TYRA N/A
- CHCT N/A
- EPS
- TYRA N/A
- CHCT N/A
- Revenue
- TYRA N/A
- CHCT $118,100,000.00
- Revenue This Year
- TYRA N/A
- CHCT $7.71
- Revenue Next Year
- TYRA N/A
- CHCT $7.53
- P/E Ratio
- TYRA N/A
- CHCT N/A
- Revenue Growth
- TYRA N/A
- CHCT 2.96
- 52 Week Low
- TYRA $6.42
- CHCT $14.76
- 52 Week High
- TYRA $29.60
- CHCT $25.00
- Technical
- Relative Strength Index (RSI)
- TYRA 48.30
- CHCT 33.12
- Support Level
- TYRA $10.71
- CHCT $15.22
- Resistance Level
- TYRA $11.66
- CHCT $16.64
- Average True Range (ATR)
- TYRA 0.63
- CHCT 0.53
- MACD
- TYRA -0.01
- CHCT -0.14
- Stochastic Oscillator
- TYRA 18.25
- CHCT 7.86
About TYRA Tyra Biosciences Inc.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are TYRA-300, TYRA-200, and TYRA-430: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.
About CHCT Community Healthcare Trust Incorporated
Community Healthcare Trust Inc is an integrated healthcare real estate company in the United States. The company owns and acquires, or finances, real estate properties that are leased to hospitals, doctors, healthcare systems or other healthcare service providers in non-urban markets. The company derives majority of its revenues from its real estate property and mortgage notes portfolio. The company's rental and mortgage interest income is recognized based on contractual arrangements with its tenants and borrowers.